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Abstract
To evaluate the pleiotropic effects to statins, we analyze the qualitative and quantitative reti-
nal changes in hypercholesterolemic rabbits after a low-dosage statin treatment. For this
purpose, New Zealand rabbits were split into three groups: control (G0; n = 10), fed a stan-
dard diet; hypercholesterolemic (G1; n = 8), fed a 0.5% cholesterol-enriched diet for 8
months; and statins (G2; n = 8), fed a 0.5% cholesterol-enriched diet for 8 months, together
with the administration of statin (pravastatin or fluvastatin sodium) at a dose of 2 mg / kg /
day each diet. The retinas were analyzed by transmission electron microscopy and immu-
nohistochemistry (glial fibrillary acidic protein). The retinal thickness of nuclear and plexi-
form layers were quantified in semi-thin sections. The results revealed that the low-statin-
treated rabbits in comparison with the hypercholesterolemic group showed: i) a more pre-
served structure in all retinal layers; ii) a significant reduction in retinal thickness; iii) a
decrease in cell death in the nuclear-and ganglion-cell layers; iv) a reduction of hydropic
degeneration in the plexiform and nerve-fiber layers; v) a preservation of astrocytes and of
the retinal area occupied by them; and vi) a better-preserved retinal vascular structure.
Our findings indicate that low doses of statins can prevent retinal degeneration, acting
on retinal macroglia, neurons and retinal vessels, despite that hypercholesterolemia
remained unchanged. Thus, the pleiotropic effects of the statins may help safeguard the ret-
inal ultrastructure.
Introduction
Hypercholesterolemia constitutes an ischemic and inflammatory risk factor in certain neurode-
generative diseases [1]. Cholesterol, the main sterol in the retina, is widely distributed in all cell
layers of the neuroretina, including the ganglion-cell layer and the nerve-fiber layer. The retina
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acquires cholesterol both by endogenous synthesis and by circulating lipoproteins [2]. The ret-
ina is capable of rapid uptake of circulating LDL via an LDLR-mediated process occurring pri-
marily in the RPE and also possibly in Müller cells [3]. Under dietary influence and in situ
synthesis, cholesterol metabolism is regulated by cell interactions, including neurons and glial
cells. Glia is an active partner of neurons, maintaining cholesterol synthesis and removal [1].
Glial-derived cholesterol has been implicated as an important source of neuronal cholesterol,
particularly for making new synaptic membranes [4]. Dysregulation of cholesterol in the retina
has been associated with retinal impairment, reflecting the key role of this sterol in neurons
[1]. Cellular cholesterol deficiency and accumulation, hallmarks of some neurodegenerative
diseases involving the retina [5,6], highlight the importance of maintaining cholesterol homeo-
stasis in neurons. Many genes historically associated with liver, intestine, and adipose choles-
terol homeostasis are expressed in retina, RPE and choroid [7,8]. Notably, the association of
several genes involved in lipid metabolism with age-related macular degeneration (AMD) has
been recently described [9]. With aging, apolipoprotein B-lipoprotein particles of unusual
composition are secreted by RPE and accumulate in Bruch’s membrane forming a lipid wall, a
precursor of the basal linear deposits seen in AMD [10]. Esterified and non-esterified choles-
terol can constitute at least 40% of drusen [11,12], which are AMD-specific lesions.
Hypercholesterolemia reportedly boosts nitric oxide synthase 2 expression in the retina,
causing lipid peroxidation and thereby leading to oxidative damage in tissues [13]. Experimen-
tal studies have demonstrated that a cholesterol-enriched diet not only induces ultrastructural
changes in the retinal macroglia, in cells of the outer and inner retina and in endothelial cells of
the retinal capillaries but also increases lipids in the retinal pigment epithelium (RPE) and trig-
gers changes in Bruch’s membrane and the choroid [14–18]. These hypercholesterolemia-
related changes, secondary to chronic ischemia in the retina, resemble those found in human
AMD [19,20].
Neuroprotection, the therapeutic paradigm designed to slow or prevent the death of neu-
rons in order to maintain physiological function has long been a goal of clinical and basic neu-
roscience when treating neurodegeneration in the brain and in the eye [21]. Some researchers
have associated 3-hydroxy-3 methylglutaryl coenzyme A reductase inhibitors or “statins” with
a reduced risk of dementia, depression [22] and open-angle glaucoma [23]. However, informa-
tion regarding statin trials in AMD are inconclusive [24,25]. Statins are prescribed to help regu-
late low-density lipoprotein-cholesterol levels [26]. However, it is now recognized that statins
also have pleiotropic effects that activate a general neuroprotective mechanism. That is, statins
may mitigate oxidative stress, stabilize the atherosclerotic plaque, restore endothelial function,
reduce blood-vessel inflammation [26–30], and favor the expression of neuroprotective genes
in the brain [31]. In rabbits fed a cholesterol diet, these pleiotropic effects have resulted from
statin doses insufficient to reduce plasma-cholesterol levels. [27,32]. In addition, we have previ-
ously demonstrated in hypercholesterolemic New Zealand rabbits that statin treatment at non-
lipid-lowering doses can prevent the progression of atherosclerotic ischemia in the different
vascular layers of the choroid [33]. As a second step of the aforementioned study, the aim of
the present work was to analyze whether besides the effects on the choroid, a dose of statins
insufficient to normalize plasma-lipid levels could improve retinal protection by acting on reti-
nal macroglia and neurons.
Material and Methods
Experimental Design
Twenty-six adult male New Zealand rabbits weighing 2.5 ± 0.5 Kg were caged separately in an
air-conditioned room with a 12-h light/dark cycle. All animals were fed a rabbit-maintenance
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diet (carbohydrates [N.F.E.] 50%, fiber 15.5%, protein 13.5%, moisture 11%, minerals 7%, and
lipids 3%; Panlab S.L. Barcelona, Spain) at least 7 days before the beginning of the experiment
and allowed ad libitum access to water. The rabbits were assigned to three groups: control (G0;
n = 10), fed a rabbit maintenance diet for 8 months; hypercholesterolemic rabbits (G1; n = 8),
fed a rabbit maintenance diet enriched with 0.5% cholesterol (U.A.R., Paris, France) for 8
months; statin (G2; n = 8), fed a rabbit standard diet enriched with 0.5% cholesterol (U.A.R.,
Paris, France) plus the administration of fluvastatin sodium (a entirely synthetic lipophilic
statin metabolized in the liver) (Novartis) at a dose of 2 mg/Kg/day (G2A; n = 4) or pravastatin
sodium (a hydrophilic statin of fungal origin) (Bristol-Myers Squibb) at a dose of 2 mg/Kg/day
(G2B; n = 4) for 8 months. Two rabbits from the hypercholesterolemic group (G1) and one
rabbit from the pravastatin group (G2A) died as a result of cutaneous infection during the
course of the experiment.
Diet consumption was checked daily and weight was recorded at the beginning of the exper-
iment and monitored monthly thereafter. The same schedule was used to monitor serum val-
ues of total cholesterol. For this, blood samples were taken from the marginal vein of the ear
and analyzed by a colorimetric reaction using a commercially available kit (BioMerieux,
France). The animals were handled following institutional guidelines, European Union regula-
tions for animal use in research, and the ARVO (Association for Research in Vision and Oph-
thalmology) statement for the use of animals in ophthalmic and vision research, and approval
by the ethical committee of Complutense University (Spain).
The rabbits were killed with an overdose of sodium pentobarbital. Eyes were enucleated
immediately after death and slit behind the limbus with a razor blade in order to facilitate pene-
tration of the fixative. For each animal, one of the eyes was used for immunohistochemistry
(n = 23) and the other one for electron microscopy (n = 23).
Transmission Electron Microscopy (TEM)
Eyes were immersed in 2% glutaraldehyde in 0.1M phosphate buffer (PB), at pH 7.4 and 4°C
for 5h. After being washed in 0.1M PB, the wall of the posterior segment of the eyes (including
the choroid, RPE, and neurosensorial retina) was diced into small pieces. These fragments were
post-fixed in 1% osmium tetroxide in 0.1M PB for 2h at 4°C. The tissues were then dehydrated
in graded acetone and embedded in araldite. The semi-thin sections (0.5μm) were stained with
toluidine blue, and after selection the blocks were further trimmed for ultramicrotomy (Reich-
ert OM-V3 ultramicrotome, Leica, Germany). The thin sections, treated with 2% uranyl acetate
in water and lead citrate for contrast, were examined by transmission electron microscopy
(TEM; Zeiss 902 electron microscope) to study the RPE and the neurosensory retina.
Immunohistochemistry
To analyze the retinal macroglia, we fixed eyes with 4% paraformaldehyde in 0.1M PB (pH 7.4)
for 4h and then processed as retinal whole-mounts with the immunohistochemical protocol
described elsewhere [34]. A monoclonal antibody directed against glial fibrillary acidic protein
(GFAP) (clone GA-5, Sigma, St. Louis, MO, USA) was used as a primary antibody in a 1/300
dilution. A negative control was performed to demonstrate that the secondary antibody reacted
only with its respective primary antibody. This control was made by eliminating the primary
antibody and replacing it with antibody buffer.
Quantification of Retinal-Layer Thickness
Quantitative analyses were made in six rabbits from each study group (G0, G1, G2). For each
animal, we measured six retinal semi-thin sections of the same retinal zones (medulated nerve-
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fiber region: MNFR). On each section, measurements in three non-adjacent retinal areas were
performed as described elsewhere [33]. Photographs were taken at 40X with a microscope
(Zeiss, Axioplan 2 Imaging Microscope). In each semi-thin section photographed, a longitudi-
nal zone of 150μmwas selected to quantify retinal-layer thickness.
The retinal thickness was measured in the following layers of the neurosensory retina: pho-
toreceptor layer (PL), outer nuclear layer (ONL), outer plexiform layer (OPL), inner nuclear
layer (INL), and inner plexiform layer (IPL). The ganglion cell layer and the nerve fiber layer
were not included in the measurements, since the retinal zone for the quantification was the
medulated nerve-fiber region (MNFR) in which the astrocytes are located. In the rabbit, this
zone is a vascularized retinal region where axons are myelinated, causing great thickness vari-
ability. The retinal thickness was manually measured using an interactive measurement tool
included in the AxioVision Release 4.8.2 computer program (Zeiss, Germany) coupled to the
microscope.
Quantitative Analysis of Retinal Astrocytes
The area occupied by astrocytes associated with the nerve-fiber bundles (AANFB) and that
occupied by perivascular astrocytes (PVA) were quantified in the retinal whole-mounts as
described elsewhere [17].
GFAP-labeled retinal area occupied by astrocytes associated with the nerve-fiber bun-
dles (AANFB-RA). Briefly, the GFAP-labeled retinal area occupied by AANFB was measured
in previously selected zones. The selection criterion was that the zones should be free of peri-
vascular astrocytes, given that their presence could distort or hamper the AANFB estimation.
In each of the MNFR, 9 zones were selected and photographed with a 20X microscopic lens,
giving an area of 0.1889 mm2 per photograph.
The resulting images were processed with the Threshold Tool of the Metamorph Imaging
System. Areas of the image that were marked in the red (as a visual indicator of the thresholded
areas) threshold overlay (GFAP+ AANFB) were included in the measurement and processing.
GFAP-labeled retinal area occupied by perivascular astrocytes (PVA-RA). In rabbits,
perivascular astrocytes (PVA) took two shapes as described elsewhere [16,17,35,36]:
1. The type I PVA had an ovoid perikaryon, producing numerous sprouting, hair-like pro-
cesses. These cells are associated with medium-sized epiretinal vessels, and with capillaries
located over the inner limiting membrane.
2. The type II PVA, star-shaped, had a spherical cell body with four to ten small radial pro-
cesses protruding from it which made contact with the vessel wall. These cells are found on
larger and medium-sized epiretinal vessels.
The GFAP+ retinal area occupied by type I PVA (PVA-I) and type II PVA (PVA-II) was
quantified as previously described for AANFB with slight modifications: i) we selected 13
zones in the centermost part of the MNFR, where the perivascular astrocytes were located; and
ii) as the areas of the image marked with the threshold overlay corresponded to the GFAP
+ astrocytes (PVA plus AANFB), to quantify just the area containing PVA-I and PVA-II, we
then selected these cells by hand using the interactive-mode tool of the Metamorph Imaging
System, which allows the selection of individual objects by clicking on them in the image
window.
Statistical Analysis
Data for the statistical analyses were introduced and processed in a SPSS 15.0 (comprehensive
statistical software; SPSS Inc). The Mann—Whitney U test was used to analyze the data of
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weights and serum-lipid values. For retinal thickness, AANFB-RA and PVA-RA differences in
means were analyzed using an ANOVA and a post hoc Bonferroni test. A value of p< 0.05 was
considered statistically significant.
Results
No statistically significant differences were found in weights and total serum cholesterol levels
between the untreated rabbits and those treated with statins (Table 1).
Since no substantial differences appeared in morphology or ultrastructural features of the
retina between statin groups, the results of G2A and G2B groups are described together as G2.
Semi-Thin Sections (Light Microscopy)
Overall, in comparison to G0 and G2, G1 rabbits exhibited several alterations in all retinal lay-
ers. In G1, retinal layers were disorganized, showing edema, empty spaces, and pyknotic nuclei,
which were not detected in G2, the latter being more similar to the G0 group (Fig 1).
Quantification of the Retinal-Layer Thickness
In G2, the thickness of the different retinal layers significantly diminished in comparison both
to G1 (p< 0.01 for ONL; p< 0.05 for OPL; p< 0.01 for INL; p< 0.01 for IPL, ANOVA in all
cases) and to G0 (p< 0.01 for PL; p< 0.05 for ONL; p< 0.05 for OPL; p< 0.01 for INL,
ANOVA in all cases) (Fig 2).
Transmission Electron Microscopy
Retinal-pigment epithelium. In G1 the retinal-pigment epithelium (RPE) cells were
hypertrophic (Fig 3B). Their cytoplasm showed numerous dense bodies and many lipid drop-
lets. These abnormalities appeared to a much lesser extent in G2 (Fig 3C). Also, basal infoldings
and microvilli were better preserved in G2 (Fig 3C) than in G1 (Fig 3B), where these structures
disappeared in some retinal sectors.
Photoreceptor Layer. In G1 (Fig 4B) the mitochondria of the photoreceptor ellipsoid
were swollen and degenerated, unlike the numerous well-preserved mitochondria detected in
G2 (Fig 4C). In G1 the outer segment of the photoreceptors formed circumvolutions (Fig 4B),
an alteration rarely found in G2 (Fig 4C).
Outer nuclear layer. In G1 (Fig 5B1 and 5B2), most cells were intensely degenerated due
to necrosis and apoptosis, and empty spaces appeared between cells. In G2 (Fig 5C1 and 5C2),
most cells were well preserved and the empty spaces visible in G1 (Fig 5B1 and 5B2) were occu-
pied by Müller-cell processes (Fig 5C1 and 5C2).
Table 1. Weights, total cholesterol serum values at the end of the experiment.
Group Mean±SEM p*
Weight (Kg) G1 3.920 ± 0.38 NS
G2 3.957 ± 0.28 NS
Cholesterol (mg/100ml) G1 1061 ± 358 NS
G2 968 ± 162 NS
* Mann—Whitney test. NS = Non-signiﬁcant; G1 (n = 8) (0.5% cholesterol-enriched diet. No treatment); G2
(n = 8) [0.5% cholesterol-enriched diet + ﬂuvastatin sodium or pravastatin sodium (2 mg/Kg/day each)].
doi:10.1371/journal.pone.0154800.t001
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Outer plexiform layer. In G1 (Fig 6B1 and 6B2), axons and dendrites were swollen, had
necrotic features, and were farther apart than in control (Fig 6A1 and 6A2); also, cells contained
numerous dense bodies. In G2 (Fig 6C1 and 6C2), alterations were similar to those of G1, but
the changes were less intense. The synaptic complexes, although visible in G1 (Fig 6B2), were
better preserved in G2, which displayed numerous synaptic vesicles, synaptic ribbon, and arci-
form densities (Fig 6C2). The empty spaces left by degenerated axons and dendrites (Fig 6A)
were occupied by the Müller-cell processes in G2 (Fig 6C1), a feature not detected in G1.
Inner nuclear layer. In G1 (Fig 6B1), most cells in this layer were degenerated, with necrotic
predominating over apoptotic features. Cell debris from necrotic and apoptotic cells were phago-
cytosed by Müller glia (Fig 6B1). G2 cells exhibited normal features or incipient stages of necro-
sis, and the empty spaces left by the latter were occupied by Müller cells (Fig 6C1).
Inner plexiform layer. In G1, axons and dendrites were swollen and exhibited different
necrotic features. Mitochondria were swollen and Müller cells were necrotic (Fig 7B). In G2
(Fig 7C), the edematous axons and dendrites appeared less frequently observed than in G1,
being more similar to control (Fig 7A). In G2 (Fig 7C), Müller cells filled the empty spaces left
by degenerated axons, while neurofilaments and mitochondria were better preserved than in
G1 (Fig 7B).
Retinal-ganglion-cell layer. In G1, almost all RGC were necrotic (Fig 8B1), their nucleo-
plasm, cytoplasm, and cytoplasmic organelles having undergone hydropic degeneration
(vacuolization, swelling, and loss of ultrastructural features). However, in G2 (Fig 8C), most of
the ganglion cells appeared normal, although some showed incipient necrosis. Apoptosis was
not found in the sections analyzed in this retinal layer.
Nerve-fiber layer. This layer showed intense abnormalities in G1 rabbits (Fig 9B). Overall,
axons exhibited hydropic degeneration, with neurofilaments and vesicles showing granular
Fig 1. Semi-thin sections (optic microscopy). In G1 the figure illustrates the overall alterations of the retinal layers: pyknotic nuclei
(arrowheads) and edema (arrows) secondary to cell degeneration. Details of pyknotic nuclei (inset). The retina in G2 was more similar to
G0; [ganglion-cell layer (GCL); inner nuclear layer (INL); inner plexiform layer (IPL); nerve-fiber layer (NFL); outer nuclear layer (ONL);
outer plexiform layer (OPL); photoreceptor layer (PL)].
doi:10.1371/journal.pone.0154800.g001
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disintegration. In some axons, small vacuoles separated the myelin sheaths. In G2 (Fig 9C)
axons were better preserved although some myelin abnormalities were visible.
Retinal astrocytes and Müller cells. In G1, some astrocytes (Fig 10B1) and Müller cells
(Fig 10B2) showed necrotic features. The best-preserved macroglial cells were reactive, with
abundant organelles, glial filaments, and clumps of electrodense material. In G2, astrocytes
(Fig 10C1) and Müller cells (Fig 10C2) showed the aforementioned signs of glial reactivation.
Only a few astrocytes of the glial tufs displayed necrotic changes.
Retinal capillaries. In G1 (Fig 11B) the basal membrane of the capillaries in the NFL and
in the vitreous humor proved thicker than in control (Fig 11A) and G2 (Fig 11C). Endothelial
cells and pericytes in G1 (Fig 11B) showed the initial stages of necrosis, but these features
were absent in G2 (Fig 11C). The vascular lumen appeared normal in both G1 and G2 (Fig 11B
and 11C).
Immunohistochemical Study of the Macroglia in Retinal Whole-Mounts
Müller Cells. In control animals (G0), GFAP immunostaining in Müller cells proved neg-
ative (Fig 12A), whereas in G1 and G2 (Fig 12B and 12C) the Müller cells were GFAP+. The
Fig 2. Retinal-layer thickness. Comparison among the three groups of study. A: The photoreceptor layer was significantly
thinner in G2 than in G0. ** p<0.01 vs. G0; B: The outer nuclear layer was significantly thinner in G2 than in G0 and in G1. ** p<0.01
vs. G1; * p<0.05 vs. G0. C: The outer plexiform layer was significantly thinner in G2 than in G0 and in G1. * p<0.05 vs. G1; * p<0.05
vs. G0. D: The inner nuclear layer was significantly thinner in G2 than in G0 and in G1. ** p<0.01 vs. G1; ** p<0.01 vs. G0; E: The
inner plexiform layer was significantly thinner in G2 than in G1. ** p<0.01 vs. G1; Each bar represents the mean ± SD. ANOVA with
Bonferroni test. ANOVA, analysis of variance. [INL: inner nuclear layer; IPL: inner plexiform layer; ONL: outer nuclear layer; OPL:
outer plexiform layer; PL: photoreceptor layer].
doi:10.1371/journal.pone.0154800.g002
Low-Dose Statins and Retinal Neuroprotection
PLOS ONE | DOI:10.1371/journal.pone.0154800 May 4, 2016 7 / 28
Fig 3. Transmission electronmicroscopy of the RPE cells. A: G0 control; B: G1 hypercholesterolemic; C:
G2 statins. The cytoplasm of RPE cell in G1 (B) shows dense bodies (*) and droplets of lipids (L) that were
less evident in G2 (C). Apical microvilli (arrow) and basal infolding (arrowhead) were better preserved in G2
(C) than in G1 (B). [Bruch’s membrane (B); choriocapillaris (CC). G2 (Pravastatin)].
doi:10.1371/journal.pone.0154800.g003
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Fig 4. Transmission electronmicroscopy of the photoreceptor layer. A: G0 control; B: G1
hypercholesterolemic; C: G2 statins. In G1 (B) the outer segment of the photoreceptors formed
circumvolutions (arrowheads) that were not detected in G2 (C). The mitochondria of the ellipsoid were
swollen (arrows) in G1 (B). In G2 (C) they were similar to those in G0 (A). [Outer segment of photoreceptors
(o); photoreceptor ellipsoid (e). G2 (pravastatin)].
doi:10.1371/journal.pone.0154800.g004
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pressure exerted by the cover glass on the retinal whole-mount caused a retinal-like section
effect in some retinal borders in which GFAP+ Müller cells were visible throughout the retina
(Fig 12B inset). In G1 and G2 retinas, outside the MNFR where the astrocytes were absent,
Müller cells were easier to recognize. These cells formed GFAP+ glial scar-like structures in G1
(Fig 12B) but not in G2 (Fig 12C).
Astrocytes. In G0, two groups of astrocytes were found: perivascular astrocytes (PVA)
(Fig 13A and 13D); and astrocytes associated with the nerve bundles (AANFB) (Fig 14A).
The former group contained two types of PVA, PVA-I (Fig 13A) and PVA-II (Fig 13D), as
described in the material and method section elsewhere.
Both in G1 (Fig 13B) and G2 (Fig 13C), GFAP PVA-I were reactive. In G1 the vascular
walls showed a strong brown-colored reaction due to the presence of thick PVA-I, in which it
was not possible to differentiate the soma from the processes (Fig 13B inset). In many retinal
vessels (mainly in the medium-sized vessels) there were large areas where this astroglial type
had disappeared (Fig 13B). In G2 (Fig 13C), PVA-I were thicker than in G0 (Fig 13A),
although, the soma and processes of these cells could be easily distinguished, unlike those from
G1. PVA-I had many processes which, in some areas, covered the entire vessel wall (Fig 13C).
In comparison to G0 (Fig 13D), PVA-II in G1 (Fig 13E) had: i) intense GFAP+ immunos-
taining; ii) a more robust cell body; and iii) longer and thicker processes which made contact
with neighboring astrocytes and vascular walls. In G1, PVA-II cells were found on and among
the vessels, particularly in those where PVA-I had disappeared (Fig 13E). In G2 (Fig 13F),
PVA-II slightly increased in GFAP+ expression as compared to G0 (Fig 13D), though less
than in G1 (Fig 13E). In addition, the morphological appearance of PVA-II was similar to that
of G0.
In G1 (Fig 14B) and G2 (Fig 14C), AANFB had thicker cell bodies and processes than in G0
(Fig 14A).
Retinal area occupied by AANFB. The comparison of the GFAP+ retinal area occupied
by AANFB (GFAP+ AANFB-RA) indicated that all the study groups differed from each other
(p<0.01; ANOVA). In comparison to G0 (0.057±0.008 mm2), GFAP+ AANFB-RA in G1
(0.029 ±0.004 mm2) was significantly reduced (p<0.01 ANOVA with Bonferroni). In addition,
Fig 5. Transmission electronmicroscopy of the outer nuclear layer. A1,A2: G0 control; B1,B2: G1 hypercholesterolemic; C1,C2: G2 statins.
In G1 empty spaces (*), and cell death by necrosis (arrow) and apoptosis (arrowhead) were detected in most photoreceptors. In G2 the signs of
cell death were less apparent, being more similar to those in G0. In G2 the spaces left by dead cells were filled by Müller cells. [Müller cells (M);
outer limiting membrane (OLM). G2 (pravastatin)].
doi:10.1371/journal.pone.0154800.g005
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in G1 the GFAP+ AANFB-RA was statistically reduced in comparison with G2 (0.050±0.008
mm2; p<0.05 ANOVA with Bonferroni) (Fig 15).
Retinal area occupied by PVA. The comparison of the GFAP+ retinal area occupied by
PVA-I and PVA-II (GFAP+ PVA-RA) showed that all the study groups differed from each
other (p<0.001; ANOVA). In comparison to G0 (0.025±0.003 mm2), GFAP+ PVA-RA in G1
(0.014±0.002 mm2) was significantly reduced (p<0.01 ANOVA with Bonferroni). However,
GFAP+ PVA-RA in G2 (0.033 ± 0.003 mm2) significantly increased in comparison with both
G0 and G1 (p<0.001 and p<0.05, respectively, ANOVA with Bonferroni) (Fig 15).
Discussion
The New-Zealand rabbit is being used as a model of experimental hypercholesterolemia
because, among other characteristics [37–43] atheromateous lesions developed by these ani-
mals are similar to those in humans [44]. It bears mentioning that, in this experimental model,
lipid deposits also occur in ocular tissues [42,45,46]. Previously, we have reported that high
Fig 6. Transmission electronmicroscopy of the inner nuclear layer and outer plexiform layer. A1,A2: G0 control; B1,B2: G1
hypercholesterolemic; C1,C2: G2 statins. The signs of necrosis in the cell bodies (*), axons, and dendrites (arrows) were less evident in G2 than in
G1. The empty spaces left by degenerated cell bodies and processes observed in G1 (B1) were occupied by processes of Müller cells in G2 (C1). The
synaptic complexes were better preserved in G2 (C2) than in G1 (B2). [inner nuclear layer (INL); inner plexiform layer (IPL); Müller cells (M); outer
nuclear layer (ONL); outer plexiform layer (OPL); synaptic complexes (S). G2C (pravastatin); G2D (fluvastatin)].
doi:10.1371/journal.pone.0154800.g006
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cholesterol levels induce chronic ischemia in the choroid and retina of New-Zealand hyper-
cholesterolemic rabbits [16,18]. Such ischemia was a consequence of the lipid deposit found in
the suprachoroidea, vascular endothelium, and Bruch’s membrane (BM). Also, previous work
in our laboratory (using the same animals as analyzed in the present study) has demonstrated
Fig 7. Transmission electronmicroscopy of the inner plexiform layer. A: G0 control; B: G1
hypercholesterolemic; C: G2 statins. In G2 (C) features of axon and dendrites necrosis (arrows) were fewer
than in G1 (B). In G2 (C) the ultrastructural characteristics of the neuronal processes were more similar to
those in G0 than in G1 (B) (A). In G2 (C), Müller cells filled the empty spaces left by necrotic cell processes
[Müller cells (M); Müller cell in necrosis (*); G2 (pravastatin)].
doi:10.1371/journal.pone.0154800.g007
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Fig 8. Transmission electronmicroscopy of ganglion-cell layer. A: G0 control; B: G1
hypercholesterolemic; C: G2 statins. In G1 (B) RGC were necrotic (*); however, in G2 (C) these cells were
more similar to those in G0 (A). [Retinal-ganglion cell (GC); G2 (Pravastatin)].
doi:10.1371/journal.pone.0154800.g008
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Fig 9. Transmission electronmicroscopy of nerve-fiber layer. A: G0 control; B: G1 hypercholesterolemic;
C: G2 statins. In G2 (C) the ultrastructural characteristic of axons were more preserved than in G1 (B) in
which they were necrotic (arrow). In G2 (C) some myelin abnormalities were found (arrowhead) to a lesser
extent than in G1 (B). [G2 (fluvastatin)].
doi:10.1371/journal.pone.0154800.g009
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that a non-lipid-lowering dose of statins improved the damage of the choroidal vessels and
BM, as revealed by electron microscopy [33]. Specifically, treatment with fluvastatin sodium
and pravastatin sodium at a non-lipid-lowering dose (2mg/Kg/day): i) prevents progressive
atherosclerosis in choroidal vessels; ii) preserves the ultrastructural characteristics of vascular
smooth-muscle cells and endothelial cells, presumably maintaining the endothelium-depend-
ing relaxation and thus diminishing ischemia; and iii) causes the disappearance of lipids in
BM [33]. All these features presumably improve oxygen and nutrient transport to the retina
[16–18].
Fig 10. Transmission electron microscopy of retinal macroglia. A1,A2: G0 control; B1,B2: G1
hypercholesterolemic; C1,C2: G2 statins. Astrocytes (A1-C1). Müller cells (A2-C2). In G1 (B1,B2), some
astrocytes and Müller cells were necrotic (*) and some others were reactive with abundant organelles, glial
filaments, and clumps of electrodense material (arrow). In G2 (C1, C2) these glial cells were reactive.
[astrocyte (A); glial filaments (F); inner limiting membrane (ILM); Müller cells (M); vitreous humor (V); G2
(fluvastatin)].
doi:10.1371/journal.pone.0154800.g010
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Fig 11. Transmission electron microscopy of retinal capillaries. A: G0 control; B: G1
hypercholesterolemic; C: G2 statins. In G2 (C) the basal membrane was thinner than in G1 (B), being more
similar to that in G0 (A). The necrotic features (arrows) observed in the endothelial cells and pericytes in G1
(B) were not found in G2 (C) [basal membrane (BM); endothelial cell (e); vascular lumen (L); pericyte (P); G2
(pravastatin)].
doi:10.1371/journal.pone.0154800.g011
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Fig 12. Changes in retinal Müller glia. Retinal whole-mount. Immunohistochemistry anti-GFAP. In G0
(A) astrocyte associated with the nerve-fiber bundles were GFAP+ (white arrow); however, immunostaining
for GFAP in Müller cells was negative. In G1 (B) and G2 (C) Müller cells were GFAP+. The pressure exerted
by the cover slip on the whole-mount caused a retinal-like section effect on one edge of the tissue, revealing
that Müller cells were GFAP+ throughout the retinal thickness (arrowhead) (B inset). Only in G1 (B) was a
glial scar-like structure observed (arrows).
doi:10.1371/journal.pone.0154800.g012
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Fig 13. Changes in type I and type II perivascular astrocytes. Retinal whole-mount. Immunohistochemistry anti-
GFAP. In G0 (A) the soma of PVA-I (arrow) could be easily differentiated from processes. In G1 (B) PVA-I were reactive and
soma could not be differentiated from processes (inset). There were large areas free of this astroglial type in many retinal
vessels (*). In G2 (C) PVA-I were reactive and somas could be distinguished from processes (arrow). PVA-I processes were
so abundant that they almost covered the vessel walls. [type I perivascular astrocyte (PVA-I)]. In G0 (D) GFAP
immunostaining in PVA-II (white square) was less intense than in PVA-I (arrow). G1 (E) contained numerous PVA-II in the
vicinity of vessels devoid of PVA-I, and the intensity of the GFAP immunoreaction was greater than in G0 (D). In G2 (F), GFAP
immunoreaction in PVA-II was lower than in G1 (E) but slightly greater than in G0 (D). In addition, PVA-II morphology in G2
resembled more G0 than G1. [type I perivascular astrocyte (PVA-I); type II perivascular astrocyte (PVA-II)].
doi:10.1371/journal.pone.0154800.g013
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Fig 14. Changes in retinal astrocytes associated with the nerve-fiber bundles. Retinal whole-mount.
Immunohistochemistry anti-GFAP. In comparison with G0 (A) astrocytes associated with the nerve-fiber
bundles in G1 (B) and G2 (C) had thicker cell bodies and processes. [AANFB: astrocytes associated with the
nerve-fiber bundles].
doi:10.1371/journal.pone.0154800.g014
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Early alterations in the sensory rabbit retina can be secondary to a hypercholesterolemic
diet [16,17,47]. However, to the best of our knowledge, no works available demonstrate that
treating these animals with a statin dose insufficient to normalize plasma lipid levels (2mg/Kg/
day) [27,48] can preserve the retinal ultrastructure. Therefore, in the present study, we offer an
in-depth report on the effects of non-lipid-lowering doses of fluvastatin and pravastatin on the
retina in hypercholesterolemic rabbits, specifically assessing: i) ultrastructural changes of the
retinal layers, retinal vessels, and retinal macroglia; ii) retinal-layer thickness; iii) GFAP+ area
occupied by retinal astrocytes and; iv) immunohistochemical changes of retinal macroglia.
Statins, selective inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA reductase, can lower
serum-cholesterol levels in humans and animals by depressing cholesterol biosynthesis [49,50].
Apart from their beneficial effects as lipid-lowering drugs, statins have additional valuable
pleiotropic properties [27–30,51], which have been reported in hypercholesterolemic rabbits at
a dose inadequate to reduce blood-cholesterol levels [27,32]. Recently, it has been reported that
in human AMD patients high-dose statints may result in drusen regression [52]. However,
studies on statins and AMD are inconclusive to date because such studies have considered all
hydrophilic and lipophilic statins together, so that an assessment of a local ocular effect is not
possible [53]. The reason for using two different statins in the present study was not to com-
pare the intensity of their respective effects, but to check whether both lipophilic (fluvastatin)
and hydrophilic (pravastatin) statins with different pharmacodynamic properties [33] were
able to protect the retina. In mice, both lipophilic (simvastatin) and hydrophilic (pravastatin)
statins reportedly cross the blood-brain-barrier (BBB) [31]. Lipophilic statins administered as
lactone forms cross the BBB directly. However, the mechanisms proposed for actively trans-
porting hydrophilic statins into the brain are organic anion transporters [54] and by the
Fig 15. GFAP-labeled retinal area occupied by astrocytes. Comparison of the three study groups. The
GFAP-labeled retinal area occupied by perivascular astrocytes (PVA-RA) in G1 (hypercholesterolemic
untreated rabbits) was significantly decreased in comparison with G0 (control). By contrast, in G2
(hypercholesterolemic rabbits treated with a low dose of statins), the PVA-RA was significantly increased in
comparison with both G0 and G1. *** p<0.001 vs. G1; ** p<0.01 vs. G0; * p<0.05 vs. G0. The GFAP-
labeled retinal area occupied by astrocytes associated with the nerve-fiber bundles (AANFB-RA) was
significantly decreased in G1 (hypercholesterolemic untreated rabbits) in comparison with G0 (control). The
comparison of G1 vs. G2 revealed that the AANFB-RA in G2 was significantly larger than in G1. ** p<0.01
vs. G0; * p< 0.05 vs. G1. Each bar represents the mean ± SD. ANOVA with Bonferroni test. ANOVA, analysis
of variance.
doi:10.1371/journal.pone.0154800.g015
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monocarboxylic acid transporter [55]. In the cerebral cortex of mouse, both hydrophilic as well
as lipophilic statins pleiotropically affected neuroprotective gene expression [31]. This could
explain why in the present study we found that both statin types caused similar effects on the
retina. Statins could contribute to neuroprotection through at least three different pleiotropic
effects: i) reduction of the oxidative damage by diminishing the production of reactive oxygen
species [56,57]; ii) improvement of vascular function by controlling nitric oxide production
[22]. Statins improved blood flow even further by suppressing the expression of the vasocon-
strictive peptide endothelin-1 [58,59] and; iii) modulation of the immune response by reducing
cytokine-induced expression of costimulatory molecules on immune cells and endothelium
and expression MHC-II class molecules. In addition, statins interact with adhesion molecules
and modulate their expression [60].
The retina is a demanding tissue in terms of cholesterol use. Retinal cholesterol comes from
two different sources: local synthesis and extra-retinal supplies. The blood-retinal barrier, in
contrast to BBB, is capable of cholesterol uptake from the circulation via a lipoprotein-based/
receptor-mediated mechanism [2]. As established in studies using systemic injection of fluores-
cently-labeled lipoprotein particles and subsequent fluorescence imaging of retinal cross sec-
tion, cholesterol from the systemic circulation can cross the RPE [3]. Thus, blood-borne
lipoproteins reach the RPE as well as the neuroretinal layers [61]. In accordance with a previ-
ous study [16], we found here that, in hypercholesterolemic rabbits, RPE cells showed intracel-
lular droplets of lipids. These lipid accumulations may occur because RPE expresses a variety
of lipoprotein-specific receptors (LDLR, SR-BI, SR-BII) and scavenger receptors (CD36) that
enable the recognition of circulating lipoproteins by RPE and delivery to the retina [1,10]. The
accumulation of lipids between the inner collagenous layer and the basal lamina of the BM (as
seen in many older human eyes) participates in creating a physical barrier, called the lipid wall,
which may limit the exchanges between the choriocapillaris and the RPE [10,62,63]. This fact
is believed to result in a lower nutrient intake by the neural retina, compromising retinal func-
tion [2,16,33].
Brain cholesterol is synthesized de novo in neurons and astrocytes [4,64,65] while, in the ret-
ina, synthesis occurs not only in these cells but also in the Müller glia [66] and RPE [24]. It has
been reported that, in mice, neither a high-cholesterol diet nor orally administered simvastatin
significantly affected retinal expression of the major cholesterol- and vision-related genes and
that these treatments had only a modest impact on the cholesterol content in the retina [67,68].
This behavior is essential for the retina, because cholesterol is a lipid source and is required to
build the vast membrane surfaces of the axons, dendrites, and synapses [69,70].
Our study demonstrates that the appearance of the retina was better preserved in hyper-
cholesterolemic rabbits receiving low-dose statins (G2) than in hypercholesterolemic rabbits
without treatment (G1). The preservation of the retinal ultrastructure found in G2 could be due
to the pleiotropic effects of statins. One such effect could be related to ischemia reduction. In
hypercholesterolemic rabbits, the use of the same statins at the same dose as used in the present
work have been found to help preserve endothelial cells in the choroidal vessels [33]. A similar
effect was noted in the retinal vessels in G2 rabbits of the current study, suggesting that an endo-
thelium-dependent relaxation is maintained, thus reducing retinal ischemia. Statins can reduce
the production of reactive oxygen species by inhibiting the activation and assembly of the
NADPH-complex [56,57], by controlling nitric oxide production, and possibly by reducing the
inflammatory response [22]. According to this scenario, the decreased cell necrosis detected in
G2 could account for the diminished cell edema in G2, and may partly explain why the thick-
ness of the different retinal layers in G2 was significantly reduced in comparison to G1.
The presence of well-known lipid transport proteins involved in HDL particles maturation
in the photoreceptor layer has been reported [61]. These molecules are involved into the uptake
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and turnover of normal (non-oxidized) lipid species in retinal cells and may also facilitate the
removal of oxidized lipids, especially those arising in the membrane of the outer segment of the
photoreceptors [61]. In the photoreceptor layer, the swollen and degenerated mitochondria
of the ellipsoid in G1 lead us to postulate that the aforementioned lipid transport system is
impaired in hypercholesterolemic rabbits. By contrast, many well-preserved mitochondria
were found in the photoreceptor layer in G2. Such mitochondrial preservation was found in
the rest of retinal layers in G2. Notably, in G2 this preservation was accompanied by fewer
necrotic and apoptotic features in these animals. It has been proposed that apoptosis can be
intensified by the release of apoptogenic factors after the opening of the mitochondrial perme-
ability transition pores, while persistent opening leads to necrotic cell death [71]. The ability of
the mitochondrial state to induce apoptosis or necrosis could help explain why the better the
mitochondrial preservation (as in animals treated with low statin doses) the lesser the retinal
cell death. This could in turn account for the fact that, in G2, features of cell death in the
nuclear layers were reduced in comparison with non-treated animals.
Statins can alter the expression of specific genes associated with apoptosis [31], thus protect-
ing the neurons from ischemic insults [72,73]. They can also reduce apoptotic transduction
signals induced by hypoxic ischemia, lowering the caspase-3 activation, the most important
protease in the apoptotic pathway [74]. The above effects of statins in apoptosis could account
for the reduced neuronal death by apoptosis found in our low-dose statin-treated group.
The analysis of the plexiform layers revealed that synaptic complexes were better preserved
in G2 in which numerous synaptic vesicles, the synaptic ribbon, and arciform density were visi-
ble. The most abundant neurotransmitter in the retina is glutamate and its accumulation pro-
motes excitotoxic neuronal death. Statins modulate glutamate receptors as well as transporter
localization and function, in addition to glutamate metabolism via glutamate synthase activity,
contributing to the antiexcitotoxic properties of statins [64,75–77]. In addition, statins stimu-
late BDNF expression [78,79]. BDNF regulates synaptic plasticity and appears to protect the
synaptic molecular complex [79].
A hypercholesterolemic diet in rabbits reportedly may induce early changes in the sensory
retina, with loss of RGC number [16,47]. In our G1, all ganglion cells were necrotic. In G2,
most of the ganglion cells presented normal features and the axons in the nerve-fiber layer
were better preserved than in G1. In vivo statin treatment has been shown to protect RGC after
ischemia-reperfusion [80,81]. It seems that statins exert neuroprotection by modulating Bcl-2,
BAX, BDNF, and heat-shock protein expression as well as activating of the Akt, Wnt, and ERK
signaling pathway, which are all known mediators of RGC survival [82].
Astrocytes and Müller cells protect the CNS from damage through a process called reactive
gliosis, which is triggered by polyetiological insults [83–85]. The upregulation of GFAP, a com-
monly used marker for reactive Müller cells, is so sensitive that it can serve as an indicator of
retinal stress, retinal injury, and Müller cell activation [86]. The retinal stress secondary to the
ischemic insult induced by hypercholesterolemia was manifested as reactive Müller cells in
both the G1 and G2 retinas. However, in the low-dose statin-treated animals the glial scar-like
structures formed by Müller cells in G1 were not detected.
The reduction of the retinal area occupied by AANFB and PVA in G1 was not detected in
G2 and, in comparison with control in G2, the retinal area occupied by the PVA increased.
Such findings could be explained by: i) the reduction in astroglial necrosis in G2 in comparison
with G1 observed with TEM and, ii) the astroglial hypertrophy that accompanies gliosis.
After different types of injuries, astrogliosis is a major event in CNS cell repair. The neuroin-
flammatory environment brought about by astrogliosis is secondary to the activation of NF-кB
by reactive astrocytes that produce TNF-α and nitric oxide [87,88] In addition, reactive astro-
cytes express several cell-adhesion molecules and chemokines which facilitate the infiltration
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of inflammatory cells to the injury site [89]. This scenario may be associated with neuronal
damage. Statins suppress neuroinflammation by blocking the activation of astroglial NF-кB
[89]. This mechanism could at least partly be the reason why neuronal damage was lowest
in G2.
In G1 retinal whole-mounts, it was observed that PVA-I disappeared from blood vessels in
some retinal areas. This occurrence could have a functional implication, given that astrocytes
and Müller cells: i) induce blood-retinal barrier properties in the retinal capillaries [90,91] by
releasing substances that stabilize tight junctions between endothelial vascular cells [90], secur-
ing immune privilege to protect neurons from the damage of an inflammatory immune
response [92] and; ii) help regulate blood flow [93] in response to changes in neuronal activity
[94] by secreting a number of molecules, such as prostaglandins, nitric oxide, and arachidonic
acid [95,96]. It bears noting that, in G2 retinas, no loss of PVA-I was detected, suggesting that
BRB and blood flow would be better maintained, perhaps accounting for the better retinal pres-
ervation and lower cell death found in low-dose statin-treated animals.
A major consequence of the astroglial decrease (observed as a reduction of AANFB-RA and
PVA-RA) in G1 could be related to the fact that these cells are an active partner of neurons by
maintaining cholesterol synthesis and removal [1]. In the retina, Müller cells and astrocytes
participate in the metabolism (supplying heterogeneous lipoprotein particles and ApoE) and
transport of cholesterol, an essential source of lipids for the maintenance of the neuronal cell
membranes [17,66,69,97], making neurons susceptible to alteration in long-term hypercholes-
terolemia. The Apo E supply to neurons by the better-preserved astroglial population observed
in the retinas of rabbits treated with low-dose statins could contribute to the maintenance of
the retinal neurons found in this group of animals. Another mechanism involved in astrocyte
neuroprotection in G2 could be the antioxidant capacity that follows the activation of these
cells. Thus, by means of enzymatic and non-enzymatic antioxidant defenses reactive astrocytes
protect neurons from free radicals [98]. The fact that in G2 the astroglial population was pre-
served and reactive moves us to postulate that their antioxidant capacity was maintained.
Conclusion
In conclusion, this study, using the New Zealand rabbit model of hypercholesterolemia, is the
first to report that a non-lipid-lowering dose (2mg/Kg/day) of fluvastatin sodium or prava-
statin sodium may prevent retinal degeneration, possibly through pleiotropic effects. This con-
jecture is based on the following observations in statin-treated animals in comparison with
non-treated ones: i) the structure of the retina in semi-thin sections looked similar to control;
ii) the ultrastructure in all retinal layers was better preserved; iii) the degeneration in the
nuclear layers decreased; iv) the hydropic degeneration in the plexiform and nerve-fiber layers
diminished; v) the anoxic edema secondary to hypercholesterolemia was reduced in all retinal
layers; and vi) retinal astrocytes and vascular structures were preserved. Our findings indicate
that low doses of statins can prevent retinal degeneration, acting on retinal macroglia, neurons
and retinal vessels, despite that hypercholesterolemia remained unchanged. Thus, the pleiotro-
pic effects of the statins may help safeguard the retinal ultrastructure.
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